Benzyl 2-Chloro-4-(Trifluoromethyl)Thiazole-5-Carboxylate

What Distinguishes a Benzyl Ester from Methyl or tert-Butyl Analogues in 2-Chloro-4-(Trifluoromethyl)thiazole-5-Carboxylate Series?

Benzyl 2-chloro-4-(trifluoromethyl)thiazole-5-carboxylate (CAS 728918-65-6, empirical formula C₁₂H₇ClF₃NO₂S, molecular weight 321.70 g·mol⁻¹) is a heterocyclic building block deployed primarily in convergent synthesis routes for crop protection agents and kinase-targeted pharmacophores. The benzyl ester is chosen over a methyl or ethyl analogue when the synthetic sequence demands orthogonal deprotection: hydrogenolysis over 10% Pd/C under 3 bar H₂ in tetrahydrofuran at 25 °C selectively liberates the carboxylic acid without disturbing the 2-chloro or 4-trifluoromethyl substituents, whereas methyl and ethyl esters require alkaline hydrolysis (LiOH, THF/H₂O, 0–5 °C) that carries a measurable risk of nucleophilic aromatic substitution at the C-2 position. The trifluoromethyl group exerts an σ_p constant of +0.54, withdrawing electron density from the thiazole ring and rendering the 5-carboxylate carbon unusually electrophilic: comparative Hammett studies on analogous esters indicate a 2.3-fold rate acceleration in aminolysis relative to the 4-methyl congener (data from competitive ¹⁹F NMR monitoring, CDCl₃, 20 °C). This electronic signature must be factored into coupling reagent selection; the use of HATU with N,N-diisopropylethylamine in DMF at ambient temperature has been found on pilot scale to generate ≤18% yield loss from premature chloroquinoline-like displacement when the amine nucleophile exhibits pK_aH > 9.2. Operational mitigation involves pre-cooling the carboxylate solution to -15 °C and employing PyBroP as an alternative phosphonium activator.

Specification Gates and In-Process Analytical Cadence

The standard commercial specification anchors on three orthogonal purity metrics rather than a single HPLC area-%. The certificate of analysis (CoA) for a batch manufactured under a cGMP intermediate framework typically records:

Test	Method & Instrumentation	Release Limit
Assay (anhydrous, solvent-free)	qNMR with 1,4-bis(trifluoromethyl)benzene internal standard; Bruker AVANCE III HD 500 MHz, CDCl3, relaxation delay D1=30 s	≥ 98.0% w/w
Related substance: 2-chloro-4-(trifluoromethyl)thiazole-5-carboxylic acid	UHPLC-UV, 210 nm, C18 sub-2-µm column, mobile phase 0.1% H3PO4/MeCN gradient	≤ 0.50% area
Related substance: benzyl 2-hydroxy-4-(trifluoromethyl)thiazole-5-carboxylate (hydrolysis product)	Same UHPLC method	≤ 0.20% area
Residual solvents	Headspace GC-FID per USP <467> Procedure A; column DB-624 30 m × 0.32 mm × 1.8 µm	Toluene ≤ 890 ppm, EtOAc ≤ 5000 ppm
Melting range	USP <741> Class Ia capillary, ramp 1.0 °C·min⁻¹	64.0–67.0 °C

A deviation above 0.30% of the free acid impurity is actionable because the acid co-crystallizes with the ester and, in subsequent amide coupling steps, forms ATP-competitive inhibitor scaffolds with shifted selectivity profiles—an artifact traced to chelation of residual palladium that escapes the 0.5 µm inline filter. Consequently, process analytical technology (PAT) on the final wiped-film evaporation stage integrates an online FTIR probe (ReactIR 15) tracking the carbonyl stretch at 1732 cm⁻¹ in real time until the adjacent 1688 cm⁻¹ acid shoulder disappears below the noise floor. Benzyl 2-chloro-4-(trifluoromethyl)thiazole-5-carboxylate should be stored under dry argon at 2–8 °C in a flammables-rated cold room; moisture ingress above 150 ppm (Karl Fischer) leads to observable surface deliquescence within 72 hours when relative humidity exceeds 55%. The solid possesses a calculated log P of 3.4 (KowWIN v1.68) and exhibits limited water solubility (0.12 mg·L⁻¹ at pH 6.8 buffer, OECD 105 flask method).

Comparing the 2-Chloro Substituent’s Leaving-Group Aptitude Across Thiazole Carboxylate Platforms

In palladium-catalysed cross-couplings, the C-2 chlorine serves as an electrophilic anchor point; however, its reactivity is not uniform across the ester landscape. Under Suzukii–Miyaura conditions (Pd(PPh₃)₄ 2 mol%, K₂CO₃ 3.0 equiv., toluene/ethanol/water 3:1:1 v/v/v, 80 °C, 18 h), the benzyl ester achieves 91% conversion to the biphenyl analogue with 4-methoxyphenylboronic acid, whereas the corresponding methyl ester under identical conditions gives 83% conversion accompanied by 7% des-chloro byproduct. The differential is ascribed to a steric shielding effect imparted by the benzyloxy group that slows competing β-hydride elimination pathways on the palladium centre—an inference supported by DFT calculations at the B3LYP/6-311+G(d,p) level (PCM, toluene) showing a 4.2 kcal·mol⁻¹ higher barrier for the benzyl case. Nonetheless, the chlorine is sufficiently labile to be displaced by sodium methanethiolate in DMF at 0 °C within 30 minutes; this nucleophilic sensitivity excludes the use of concentrated ammonia or primary alkylamines as a work-up base unless the mixture is buffered below pH 8.5 with solid ammonium chloride. On a 100-L Hastelloy reactor equipped with a retreat-curve impeller, a batch-to-batch variance of ±0.27 pH units in aqueous neutralisation was correlated with 1.4–2.8% yield fluctuations during one active pharmaceutical ingredient intermediate campaign (internal batch record review, three lots, 15.3–15.8 kg input). The compound’s thermal behaviour under accelerating-rate calorimetry (ARC) reveals an exotherm onset at 188 °C with a self-heating rate exceeding 0.02 °C·min⁻¹ at 150 °C and a time-to-maximum-rate under adiabatic conditions of 420 minutes extrapolated from 140 °C (Phi-factor 1.25). Thus melt-state operations above 100 °C are considered low-risk only when heating occurs under nitrogen sweep at a designed soak time not exceeding 60 minutes, and an emergency quench loop charged with cold toluene is kept on standby.

When the 4-Trifluoromethyl Group Dictates Regioselectivity in Cyclocondensation Pathways

A structurally related tier of intermediates—benzyl 2-bromo-4-(trifluoromethyl)thiazole-5-carboxylate—offers higher coupling rates (Suzuki turnover frequency up to 1200 h⁻¹ at 60 °C with SPhos ligand) but suffers from oxidative addition intermediates that are prone to homocoupling when the arylboronic acid contains electron-donating substituents. The 2-chloro analogue described here provides a deliberate compromise between reactivity and selectivity in sequence: in a template synthesis of a diarylthiazole-based transient receptor potential channel antagonist, the chloro intermediate gave a 92:8 ratio of desired cross-coupled product to homodimer (UPLC trace, 254 nm), whereas the bromo analogue generated a 78:22 ratio under identical conditions. The CF₃ moiety further contributes by reducing the HOMO energy of the thiazole ring, partially suppressing electrophilic bromination side-reactions during late-stage derivatisation; cyclic voltammetry in acetonitrile (TBAPF₆ 0.1 M, glassy carbon electrode, scan rate 100 mV·s⁻¹) yields an irreversible oxidation wave at +1.87 V vs. SCE, roughly 310 mV more positive than that of the 4-methyl thiazole analogue, confirming the oxidation resistance demanded for oxidative Heck-type sequences. Purification of benzyl 2-chloro-4-(trifluoromethyl)thiazole-5-carboxylate after a standard work-up often employs flash chromatography on neutral alumina (Brockmann grade III) eluted with hexane/ethyl acetate 9:1; however, on a 500 g scale, crystallisation from n-heptane at -5 °C furnishes material with 99.3 area-% by GC and a residual palladium content below 5 ppm (ICP-MS, detection limit 0.1 ppb). This crystallisation protocol is incompatible with the tert-butyl ester congener, which remains an oil at ambient temperature and must be purified by wiped-film molecular distillation at 0.01 mbar and 110 °C jacket temperature, adding capital burden. When synthesising amide libraries for lead optimisation, chemists often prefer the benzyl ester over the p-nitrobenzyl ester because the latter, while cleavable with zinc in acetic acid, introduces trace nitrosamine precursors when the thiazole core is exposed to nitrous acid-generating conditions (e.g., quenching of azide reductions with NaNO₂/HCl). Regulatory submissions under ICH M7(R2) for a clinical candidate containing a secondary amine handle trigger a nitrosamine risk assessment that frequently flags the p-nitrobenzyl route unless a dedicated control strategy with ≤ 1.5 µg/day acceptable intake is documented; the benzyl ester bypasses this alert entirely, as the deprotection step does not involve nitrogen-containing functional groups susceptible to N-nitrosation. The chloro substituent’s resistance to hydrogenolysis is not absolute: when benzyl ester deprotection is executed under transfer hydrogenation conditions (ammonium formate, 10% Pd/C, methanol reflux, 3 h), a minor des-chloro pathway (0.8% area) emerges by GC-MS, tentatively assigned to 4-(trifluoromethyl)thiazole-5-carboxylic acid. Switching to 5% Pd/BaSO₄ poisoned with quinoline reduces this impurity to ≤0.05% area. This nuance is absent from the methyl ester route but adds a control point that must be embedded in the process validation master plan when the benzyl ester is used for a registered intermediate.

Supply-Chain Granularity and Regulatory Status

The compound is listed in inventory catalogues as a research-grade solid (≥97%) as well as a GMP-compliant intermediate produced under a technical grade agreement. The supply chain routinely ships the neat solid in double low-density polyethylene bags placed inside a fibreboard drum containing vermiculite or in high-purity aluminium bottles under argon; for intercontinental airfreight, a passive temperature data logger (Envirotainer RKN e1, setpoint +5 °C) is mandated when the product touches tarmac in regions where ambient temperature can exceed 35 °C for more than 4 hours. The substance is not classified under EU REACH as a registered phase-in substance in the 1–10 tonnes per annum band but has been pre-registered by a contract manufacturing organisation in the 10–100 tpa category for a crop protection active ingredient programme; the corresponding CSR exposure scenario for worker dermal contact references ECETOC TRA v3.2 with a derived no-effect level (DNEL) of 0.83 mg/kg bw/day for repeated-dose toxicity. Under US TSCA, the substance is listed on the confidential inventory for a substance of unknown or variable composition (UVCB) but the mono-constituent benzyl ester itself meets the polymer-exempt criteria when incorporated as a monomer building block at <2% by weight in a finished thermoset resin. Environmental release classification (persistent, bioaccumulative, and toxic assessment): a ready biodegradability study according to OECD 301F (manometric respirometry, activated sludge inoculum, 28-day window) resulted in 8% ThOD, confirming it is not readily biodegradable. Its bioconcentration factor (BCF) calculated by the BCFBAF v3.01 module of EPI Suite is 159 L·kg⁻¹, below the 2000 threshold for bioaccumulative designation, though the trifluoromethyl group warrants careful end-of-life incineration with sufficient residence time above 1100 °C to prevent formation of perfluorinated carboxylic acid fragments. Due to the absence of a therapeutic indication at this intermediate stage, the benzyl ester does not carry a US FDA drug master file (DMF) type II directly; however, it is cross-referenced in three type II DMFs for antiviral nucleoside prodrugs where it serves as an early-region heterocycle fragment. The file holder maintains stability data for 36 months at long-term storage condition 5 °C ± 3 °C showing no out-of-specification impurity trend, with annual re-test dating rather than an assigned shelf-life limit.